Taltz (ixekizumab) is a prescription medication that is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is an injectable biologic medication that works by targeting and inhibiting a substance known as interleukin-17A, which is involved in inflammation.
Taltz is generally administered once every two weeks as an injection into the skin or taken once every four weeks as a subcutaneous injection. The dosage is determined based on the patient’s individual medical history and response to treatment.
Clinical studies have demonstrated that Taltz is effective in treating moderate to severe plaque psoriasis in both adult patients who are candidates for systemic therapy or phototherapy. Taltz has also shown positive results in treating psoriatic arthritis and ankylosing spondylitis which are same inflammatory conditions that chronic psoriasis patients may also have.
Taltz is administered using the Taltz autoinjector, or a prefilled syringe following the technique and instruction given by the healthcare provider.
Like any medication, taking Taltz can lead to side effects. Common side effects include upper respiratory tract infections, injection site reactions, and headache. Other serious side effects may include allergic reactions, infections, and worsening of inflammatory bowel diseases such as Crohn’s and ulcerative colitis. Before engaging with the therapy, the patients should make sure that they do not have tuberculosis, hepatitis B, or any other infection. Thus, patients should be carefully evaluated and monitored throughout the course of treatment.
In conclusion, Taltz (ixekizumab) is a valuable treatment option for people with moderate to severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis; chronic conditions linked to inflammation. The medication mainly works by inhibiting a protein known as interleukin-17A which is involved in inflammation. Taltz offers benefits to many patients who are candidates for systemic therapy or phototherapy and has demonstrated to improve the condition and quality of life of psoriasis patients. As with any medication, patients should be aware of the risks associated with Taltz and should discuss these with their healthcare providers prior to initiating therapy.
Reviews
There are no reviews yet.